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The continuum of HIV care is a simple conceptual
framework for monitoring HIV programmes, comprising
a series of stages that people living with HIV (PLHIV)
pass through to access antiretroviral treatment (ART) and
achieve viral suppression [1,2]. Individual benefits of
suppression include reduced risk of morbidity and
mortality. At the population level, viral suppression
reduces the risk of onward transmission and enables
epidemic containment [3]. Transmission risk may be
further reduced by lowering the number of undiagnosed
PLHIV [4,5]. Complete continua are, therefore, con-
structed beginning with the total number of PLHIV in a
given population and ending with the number virally
suppressed. Intervening stages have included the numbers
diagnosed, linked to HIV care, retained in care, eligible
for ART, on ARTand adhering to ART. Although people
can move between stages, the continuum is typically
conceptualized as a ‘snapshot’ at one time-point.
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suppressed [6], interest in constructingHIV care continua to
informnational programmes and policies has grown [7–11].
However, there has been limited consistency in themethods
used to construct these measures and the stages presented in
publications. Key stages are often missing or continua
entirely absent for many countries, including in Europe,
particularly theEastern region [7,8,11–15].Drawing from a
review of recent literature and expert opinion, we highlight
the methodological inconsistencies, the challenges associat-
ed with constructing each stage and recommend a
standardized way forward for monitoring the continuum
of HIV care in Europe.Methodological inconsistencies and
challenges
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2054 AIDS 2017, Vol 31 No 15overlooked [16]. Methodological differences make it
difficult to compare estimates between countries or to
combine data to produce regional or global estimates [13].
Initial attempts have been made to standardize definitions
in Europe [17] and globally [11,18,19], though further
support is needed [13].
The first stage, the total number of PLHIV, is the crucial
denominator against which all subsequent estimates are
measured. Yet, it is often ignored or omitted because of
methodological challenges in its estimation [7,8,20]. In
continua in which it is included, estimation methods are
diverse, with each of thirteen continua included in a
recent systematic review by using a different data source
and methodology to estimate this stage [7].
Unlike stage 1 which, by definition, must be estimated,
subsequent stages can be directly observed given complete
surveillance. As such, stage 2, the population diagnosed, is
more frequently reported and definitions are more
consistently applied [20]. Most frequently, all individuals
ever diagnosed since the beginning of the epidemic and
still alive are included, although a minority of continua
apply a narrower time window and several have
difficulties excluding deaths or out-migrations [12,20].
Definitions for linkage to and retention in care are
particularly diverse [8,12,20,21]. Being linked to caremay
include anyone enrolled in a clinical cohort, or those who
started receiving care within a specific time frame
following diagnosis [12,21–23]. A variety of measures of
‘receiving care’ are used to define linkage or retention,
such as the availability of CD4þ cell counts, viral loads,
other laboratory measurements or recorded clinic visits
[12,22]. Such differences reflect the diversity in health
systems, frequency of follow-ups and data availability in
each country [13], which renders these stages incredibly
challenging to standardize or monitor at a European level,
leaving some countries unable to measure them at all [13].
Misclassification of patients at these stages will also affect
estimates for dependent downstream stages [24,25].
Inconsistencies in the definitions of ‘being on ART’
include estimates based on prescribed or dispensed drugs
[7], exclusion of mono-drug or dual-drug regimens [26]
or of those who discontinued therapy [12], or applying a
minimum time on ART [13]. Moreover, the term ‘on
ART’ is imprecise, as continua rarely measure adherence
to treatment [8,21]. In some cases, in which prevailing
guidelines recommend ART initiation below specific
CD4þ cell count thresholds, the proportion on ART is
restricted to those eligible for treatment [8,27].
For the final stage, thresholds used to define viral
suppression differ, as does the timing of measurement,
for example last or any suppressed viral loads
[7,8,12,13,16,21], although this detail is often omitted
[7,28].Towards a standardized four-stage HIV
care continuum
We recommend that European countries focus efforts on
constructing and reporting the following four priority
stages: stage 1, the number of PLHIV; stage 2, the
number/proportion diagnosed; stage 3, the number/
proportion on ART; and stage 4, the number/proportion
virally suppressed (Table 1). These four stages accord with
the UNAIDS 90–90–90 target and, measured as a
‘snapshot’, or cross-section in time, are most important
from a public health perspective to infer the number with
detectable viral loads with the potential for transmitting
HIV. Our recommendations reflect a consensus reached
by a broad group of European experts convened by the
European Centre for Disease Prevention and Control
(ECDC) to discuss optimal approaches to constructing
HIV-care continua [22]. They are also consistent with
frameworks recently applied and opinions emerging at a
global level [8,12,13,20]. Further work is required to
develop guidance for measuring linkage to and retention
in care, as these intervening stages are important quality of
care indicators and process measures, although the
diversity in data sources and definitions remains a barrier
to standardization at this time.
The denominator of PLHIV should include all HIV-
positive individuals, diagnosed and undiagnosed, living in
the country at the end of a given year. Likewise, stage two,
by definition depends on the first stage and should,
therefore, ideally be the proportion of PLHIV ever
diagnosed, including in-migrations and excluding deaths
and out-migrations by the end of the given year. This is
inherently challenging, as it relies on cumulative HIV
surveillance data since the beginning of the epidemic,
linked to reliable death and migration data, or complete
case surveillance data for recent years in which all those
living with diagnosed HIVare reported through ongoing
monitoring, for example of CD4þ or viral loads.
Approaches to estimating the total PLHIV include back-
calculation models to estimate HIV incidence and time
from infection to diagnosis, prevalence surveys, multipa-
rameter evidence synthesis and use of Spectrum software
[32]. Back-calculation or other modelling approaches
incorporating routinely collected HIV surveillance data
may be most suitable for the concentrated HIVepidemics
in Europe [30,32–38]. ECDC has developed a modelling
tool [29] to support countries in generating robust
estimates for PLHIV by using HIV surveillance data.
However, many countries in the European region lack
HIV surveillance data for earlier years of the epidemic, or
their data suffer from substantial under-reporting. In such
cases, it is impossible to derive the number ever diagnosed
directly from surveillance data and, therefore, challenging
to produce robust estimates of PLHIV. Methods are being
developed to capitalize on available years of data, for
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2056 AIDS 2017, Vol 31 No 15example by using CD4þ data [39] or through statistical
modelling to reconstruct data for earlier years [40].
Triangulation with other data sources, such as national
clinic-based surveys to estimate the number diagnosed
and in care/not in care [37], or using health insurance
data [41], may offer alternative solutions. As in the
United States [7,16], European countries also encounter
difficulties accounting for migration and deaths, which
are often incompletely captured through surveillance
data, particularly non-AIDS-related deaths. Although
longer term solutions are clearly required, for example
enhancing surveillance systems to enable linkage to
national migration and death records via unique
identifiers [42], in the short-term, deaths and out-
migrations should at least be estimated and excluded from
each stage. Efforts to account for in-migration,
distinguishing new HIV infections after arrival in the
country, are also warranted [43].
Regarding the number ‘on ART’, we suggest that all
patients who received or were prescribed ART at least
once during the year of interest are included. This has
been recommended by the International Association of
Providers of AIDS Care (IAPAC) [18] and aligns with the
WHO indicator ‘currently on ART’ [28]. Although ART
initiation is most commonly used to measure ‘on ART’,
recent follow-up records for those continuing on ART
are also available in many European countries and other
regions [8,12,44,45]. For consistency in global and
regional reporting, and given that individuals not yet
eligible for ART can potentially transmit HIV, it is
important that the proportion on ART is not restricted to
those eligible for ART based on prevailing treatment
guidelines [14,28]. Rather, differences in guidelines,
together with epidemic contexts, should be considered
when interpreting and comparing national continua [14],
or evaluating ART programme performance within
countries [28]. However, treatment guidelines will
become less important in explaining differences in the
proportions on ART, as European and global guidelines
converge on immediate ART initiation [46,47].
For the final stage, we recommend using a cross-sectional
‘snapshot’ of viral loads at a particular time point [28], for
example the latest viral loads recorded in the year of
interest [18]. Although this single measure may overesti-
mate suppression by discounting time spent above the
threshold during the year [18,21,48], it is transparent and
easy to communicate to policy makers. It is also easier to
standardize andmeasure, particularly for countries lacking
cohort data, than other longitudinal measures of interest
[14,28,34,44] that require further development. To allow
for changes over time in the lower detection limits of viral
loads assays, we recommend using a viral load threshold of
less than 200 copies/ml. A threshold of 200 copies/ml for
population-level monitoring is consistent with recom-
mendations from a recent systematic review [7], guide-
lines produced by IAPAC [18] and the US Centers forDisease Control and Prevention [23] and recent data
published on transmission potential [49]. Although the
WHO-suggested threshold of 1000 copies/ml may be
more suitable at a global level [28], less than 200 copies/
ml is considered appropriate for European countries.Initiatives to improve monitoring of the
care continuum
Attempts to construct national-level continua have often
revealed gaps in data availability. Data for downstream
stages, particularly viral suppression, are often only
available through clinical cohorts and less frequently
reported than the number diagnosed [12,20], which may
be derived from publicly available surveillance data.
Collaboration between those responsible for case
surveillance and cohorts may facilitate construction of
complete national-level continua [17,50]. Use of cohorts
for multiple stages can improve the internal consistency of
estimates [51], if representativeness is rigorously assessed
and data are appropriately weighted to overcome
potential biases and allow generalizability of findings
[52]. European countries should also be encouraged to
establish patient monitoring systems in all facilities that
care for HIV patients [28].
Initiatives are needed to disaggregate HIV continua by
populations of interest to target testing and treatment
programmes appropriately. Few such continua have been
published in Europe [41,53]. A key challenge relates to
missing data for transmission group, as they are not
collected, sometimes owing to legal restrictions, recorded
or disclosed. Population-based bio-behavioural surveys,
incorporating the collection and measurement of
biological markers of HIV infection and treatment may
capture the whole universe of a particular subgroup
through carefully designed recruitment approaches [54].
For many European countries, modelling approaches
using routine surveillance data, in which transmission
group is collected and, if appropriate, missing informa-
tion is imputed, may be a more feasible alternative [41].Conclusion
In summary, we recommend that European countries
monitor a standardized four-stage HIV continuum of
care that aligns with the UNAIDS 90–90–90 frame-
work. Our recommendations are based on expert
opinion [22] and evidence from published literature
and may apply to other countries beyond Europe.
Additional stages of the continuum remain important as
they may provide insights related to the quality of care
and programme performance. Further guidance on
Monitoring the HIV care continuum in Europe Gourlay et al. 2057standardization of definitions, support to countries, for
example in estimating the total number of PLHIV, and
investments in data collection and measurement [28,42],
for example establishing pseudo-cohorts or linking to
death/migration records, are needed urgently if we are to
have faith in our estimates as we progress towards, reach
and surpass the 90–90–90 target in Europe.Acknowledgements
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